Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus

Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin

(2013) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

(2012) L. A. Morrow et al.   DIABETES OBESITY & METABOLISM

Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp

(2012) Hans Ericsson et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Glucokinase Activators AZD6370 and AZD1656 Do Not Affect the Central Counterregulatory Response to Hypoglycemia in Healthy Males

(2012) Ensio Norjavaara et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656

(2012) Michael J. Waring et al.   MedChemComm

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

(2011) G. E. Meininger et al.   DIABETES CARE

Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study

(2010) Riccardo C. Bonadonna et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Assessing the potential of glucokinase activators in diabetes therapy

(2009) Franz M. Matschinsky   NATURE REVIEWS DRUG DISCOVERY

Molecular Physiology of Mammalian Glucokinase

(2008) P. B. Iynedjian   CELLULAR AND MOLECULAR LIFE SCIENCES

The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies

(2008) SU Yasuda et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Glucokinase activators in diabetes management

(2008) Matthew Coghlan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS